Outlook Therapeutics Total Assets Growth & History (OTLK)
Outlook Therapeutics's total assets was $18.6M for fiscal 2025.
View full Outlook Therapeutics company overviewOutlook Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $18.6M | −$10.2M | −35.52% |
| 2024 | 2024-09-30 | $28.8M | −$3.5M | −10.77% |
| 2023 | 2023-09-30 | $32.3M | $3.8M | +13.23% |
| 2022 | 2022-09-30 | $28.5M | $5.7M | +25.06% |
| 2021 | 2021-09-30 | $22.8M | $3.1M | +15.60% |
| 2020 | 2020-09-30 | $19.7M | $2.6M | +15.16% |
| 2019 | 2019-09-30 | $17.1M | −$5.1M | −23.10% |
| 2018 | 2018-09-30 | $22.3M | $1.5M | +7.47% |
| 2017 | 2017-09-30 | $20.7M | −$4.7M | −18.39% |
| 2016 | 2016-09-30 | $25.4M | −$9.6M | −27.43% |
| 2015 | 2015-09-30 | $35.0M | — | — |
Outlook Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $26.2M | $3.8M | +16.94% |
| Q2 2026 | 2026-03-31 | $21.9M | $2.8M | +14.77% |
| Q1 2026 | 2025-12-31 | $18.2M | $1.2M | +7.25% |
| Q4 2025 | 2025-09-30 | $18.6M | −$10.2M | −35.52% |
| Q3 2025 | 2025-06-30 | $22.4M | −$24.7M | −52.45% |
| Q2 2025 | 2025-03-31 | $19.1M | −$40.0M | −67.68% |
| Q1 2025 | 2024-12-31 | $17.0M | −$4.7M | −21.58% |
| Q4 2024 | 2024-09-30 | $28.8M | −$3.5M | −10.77% |
| Q3 2024 | 2024-06-30 | $47.1M | $2.6M | +5.95% |
| Q2 2024 | 2024-03-31 | $59.0M | $5.0M | +9.26% |
| Q1 2024 | 2023-12-31 | $21.7M | −$41.0M | −65.41% |
| Q4 2023 | 2023-09-30 | $32.3M | $3.8M | +13.23% |
| Q3 2023 | 2023-06-30 | $44.4M | $5.9M | +15.18% |
| Q2 2023 | 2023-03-31 | $54.0M | −$13.7M | −20.18% |
| Q1 2023 | 2022-12-31 | $62.7M | −$16.0M | −20.32% |
| Q4 2022 | 2022-09-30 | $28.5M | $5.7M | +25.06% |
| Q3 2022 | 2022-06-30 | $38.6M | $5.7M | +17.35% |
| Q2 2022 | 2022-03-31 | $67.7M | $22.6M | +50.04% |
| Q1 2022 | 2021-12-31 | $78.7M | $66.2M | +528.52% |
| Q4 2021 | 2021-09-30 | $22.8M | $3.1M | +15.60% |
| Q3 2021 | 2021-06-30 | $32.9M | $2.6M | +8.73% |
| Q2 2021 | 2021-03-31 | $45.1M | $31.9M | +242.54% |
| Q1 2021 | 2020-12-31 | $12.5M | $2.1M | +20.10% |
| Q4 2020 | 2020-09-30 | $19.7M | $2.6M | +15.16% |
| Q3 2020 | 2020-06-30 | $30.2M | −$3.0M | −8.95% |
| Q2 2020 | 2020-03-31 | $13.2M | −$4.0M | −23.31% |
| Q1 2020 | 2019-12-31 | $10.4M | −$8.3M | −44.29% |
| Q4 2019 | 2019-09-30 | $17.1M | −$5.1M | −23.10% |
| Q3 2019 | 2019-06-30 | $33.2M | −$871,947 | −2.56% |
| Q2 2019 | 2019-03-31 | $17.2M | −$10.6M | −38.20% |
| Q1 2019 | 2018-12-31 | $18.7M | −$13.6M | −42.03% |
| Q4 2018 | 2018-09-30 | $22.3M | $1.5M | +7.47% |
| Q3 2018 | 2018-06-30 | $34.1M | $17.0M | +99.02% |
| Q2 2018 | 2018-03-31 | $27.8M | $10.3M | +59.14% |
| Q1 2018 | 2017-12-31 | $32.3M | $11.8M | +57.86% |
| Q4 2017 | 2017-09-30 | $20.7M | −$4.7M | −18.39% |
| Q3 2017 | 2017-06-30 | $17.1M | −$15.9M | −48.09% |
| Q2 2017 | 2017-03-31 | $17.5M | −$7.4M | −29.68% |
| Q1 2017 | 2016-12-31 | $20.4M | — | — |
| Q4 2016 | 2016-09-30 | $25.4M | −$9.6M | −27.43% |
| Q3 2016 | 2016-06-30 | $33.0M | — | — |
| Q2 2016 | 2016-03-31 | $24.8M | — | — |
| Q4 2015 | 2015-09-30 | $35.0M | — | — |
Outlook Therapeutics total assets trends
Over the last five fiscal years, Outlook Therapeutics's total assets decreased from $19.7M to $18.6M, a change of −$1.1M. The latest reported quarter, Q3 2026, shows $26.2M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Outlook Therapeutics source filings ↗